This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Stopped Study early terminated due to low enrollment compared to the anticipated figures.

Conditions

• Non-small Cell Lung Cancer

Interventions

• DRUG: Canakinumab
• DRUG: Pembrolizumab

Sponsor

Novartis Pharmaceuticals